Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

Zaga64 Mar. 4 at 10:42 PM

$SCYX $1+ coming

0 · Reply

Zaga64 Mar. 4 at 10:40 PM

$SCYX SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

0 · Reply

Zaga64 Mar. 4 at 10:39 PM

$SCYX “Looking ahead, SCYNEXIS remains well positioned to explore a number of opportunities to enhance shareholder value, including releasing Phase 1 data from our SCY-247 intravenous (IV) formulation study later this year.”

0 · Reply

XZeroDelta Mar. 4 at 9:26 PM

$SCYX FYI https://ir.scynexis.com/news-events/press-releases/detail/359/scynexis-reports-full-year-2025-financial-results-and

0 · Reply

StockNews_Live Mar. 4 at 9:20 PM

$SCYX SCYNEXIS received a one-time non-refundable payment of $24.8 million from GSK in Q4 2025. The company also announced the dosing of the first patient in a Phase 1 study using the intravenous (IV) formu…

0 · Reply

RisingMoons Mar. 4 at 9:13 PM

$SCYX $VNRX $AMZE $REKT.X 1

0 · Reply

d_risk Mar. 4 at 9:06 PM

$SCYX - SCYNEXIS Inc - 10K - Updated Risk Factors SCYX risk focus shifts from ibrexafungerp/BREXAFEMME to new candidate SCY-247, while adding a material listing risk: Nasdaq has formally notified the company of sub-$1 bid price, with a hard compliance deadline of June 15, 2026 and potential delisting if not cured. 🟢 Added 🟠 Removed https://d-risk.ai/SCYX/10-K/2026-03-04

0 · Reply

btm811 Mar. 4 at 9:02 PM

$SCYX

0 · Reply

SnapCrackleStop Mar. 4 at 5:37 PM

$SCYX Ok we just need one 1mm share buy to get us back to $1. Anyone? Buehler? $$$

0 · Reply

LemuelPitkin Mar. 3 at 1:58 AM

$SCYX Beware the trolls, FUD, and shorts. Scynexis has won $35MILLION in NIH grants to pay for further drug development. For some reason this little detail escapes some peeps. In addition, new rule changes and fast track status will minimize costs for further development of Scy-247. For instance, one well run phase 2 and phase three studies are now sufficient to meet FDA requirements for approval. These development are all since November of 2025. Yet you will find these doom prophets riding in on their red tricycles making the same arguments they did last year. Brexafemme rollout? When? Soon.

0 · Reply

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 8:23 AM EST - 6 days ago

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

Feb 17, 2026, 8:00 AM EST - 15 days ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CRVO

Dec 22, 2025, 8:00 AM EST - 2 months ago

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 19, 2025, 7:00 AM EST - 3 months ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Nov 5, 2025, 4:20 PM EST - 4 months ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 15, 2025, 8:00 AM EDT - 5 months ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Sep 4, 2025, 8:30 AM EDT - 6 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Aug 13, 2025, 4:30 PM EDT - 7 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 8:30 AM EDT - 10 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Mar 12, 2025, 5:08 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 2, 2024, 10:04 AM EDT - 2 years ago

Scynexis: Update Following Restructuring Of GSK Deal

Mar 28, 2024, 4:01 PM EDT - 2 years ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Jan 29, 2024, 5:15 PM EST - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 8, 2024, 4:00 AM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 4, 2024, 7:00 AM EST - 2 years ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 2 years ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:46 PM EST - 2 years ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:15 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 29, 2023, 7:50 PM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 2 years ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 2 years ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Zaga64 Mar. 4 at 10:42 PM

$SCYX $1+ coming

0 · Reply

Zaga64 Mar. 4 at 10:40 PM

$SCYX SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years

0 · Reply

Zaga64 Mar. 4 at 10:39 PM

0 · Reply

XZeroDelta Mar. 4 at 9:26 PM

$SCYX FYI https://ir.scynexis.com/news-events/press-releases/detail/359/scynexis-reports-full-year-2025-financial-results-and

0 · Reply

StockNews_Live Mar. 4 at 9:20 PM

0 · Reply

RisingMoons Mar. 4 at 9:13 PM

$SCYX $VNRX $AMZE $REKT.X 1

0 · Reply

d_risk Mar. 4 at 9:06 PM

0 · Reply

btm811 Mar. 4 at 9:02 PM

$SCYX

0 · Reply

SnapCrackleStop Mar. 4 at 5:37 PM

$SCYX Ok we just need one 1mm share buy to get us back to $1. Anyone? Buehler? $$$

0 · Reply

LemuelPitkin Mar. 3 at 1:58 AM

0 · Reply

ViktorSinclair Feb. 27 at 3:19 PM

$SCYX Let’s assume that 247 will go thru trials unscathed… as i think it should most likely. how long will it be before they see revenue from this drug? it is at least 5 more years from now. how will they make it to that point? they keep saying they are exploring non dilutive type funding? Partnerships? (if so with who)., Loans? (debt). Deals? They are not finished with phase 1 and don’t have the money to really get into a phase 2 no less finish that. and phase 3 is a pipe dream at this point and marketing??? we saw how they handled that with brexa. utter failure. David needs to explain the plan, in detail and clearly lay out how he plans to get the finish line. if he can’t he should sell the company and stop looking for helicopter money.

2 · Reply

BioRich Feb. 26 at 3:29 PM

$TLSA $SCYX $NGEN Thanks to @DataJim for getting me focused on $SCYX. The timing was perfect as they've started dosing, which is an exciting milestone. I've not started a nice position in it. Already have a nice position in $TLSA and will review $NGEN to see if I hop in there as well. Again, thanks @DataJim for the suggestions. They/you're on the list of suggestions and suggestors. Let's see how it plays out. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

6 · Reply

whob007 Feb. 26 at 3:12 PM

$SCYX the dosing should drive most stock throught he roof given the fast track desigantion

0 · Reply

whob007 Feb. 26 at 3:10 PM

$SCYX SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

0 · Reply

Zaga64 Feb. 26 at 2:11 PM

$SCYX "On January 21, 2026, the Company announced that the U.S. Food and Drug Administration (FDA) granted SCY-247 both Qualified Infectious Disease Product (QIDP) and Fast Track designations". "SCYNEXIS continues to explore potential non-dilutive funding opportunities to further support the SCY-247 program".

0 · Reply

XZeroDelta Feb. 26 at 2:02 PM

$SCYX FYI https://ir.scynexis.com/news-events/press-releases/detail/358/scynexis-announces-first-participants-dosed-in-a-phase-1

0 · Reply

ImadogImaMut Feb. 26 at 1:04 PM

$SCYX Nice increasing volume and over 100 k in dark pool traded yesterday and 2x overall volume ✅👏🎯volumes need up for bigs to cover . Off topic but Six chair s $35 cdn that is nice to have extra chairs so new seat cushion s on a 1950 s all original Canadian made set of chairs. Love love love antiques thrifting. I’ve been at it 30 +years so the rookies with their cameras an AI just slow them down he he

0 · Reply

XZeroDelta Feb. 26 at 12:15 PM

$SCYX remember folks, no risk, no reward. We just need confirmation of GSK speaking to the FDA before june and/or Hansoh confirming the first sale of ibrexafungerp in China. We have 4 months on the timer. Diamond hands

0 · Reply

Zaga64 Feb. 25 at 3:28 PM

$SCYX Whoever controls and manipulates the stock price is doing a great job. This is one of the most manipulated biotechnology stocks I have ever purchased.

1 · Reply

Jaysonpage Feb. 25 at 1:37 PM

$SCYX

0 · Reply

Jaysonpage Feb. 25 at 11:56 AM

$SCYX Should we do a comparison to Basilea Pharmaceutica AG. At ~$54 /share they trade at 10x earnings. Note there are only 12M shares - must have been a reverse split in the past. If you divide by four to get to SCYX share numbers, they would be $13.5/share. From 2021 to today, their EPS went from negative to positive and they are now coming out of the hole they have been in. Similar trend. Granted SCYX is in a bigger hole, but even at $20M/yr in earnings, with 60M shares (to account for executed warrants, which it looks like Basilea had too), we are at 0.33 EPS X a P/E of 10 gets SCYX to 3.30/share. Am I missing something? To get to 20M in earnings we need 60M in revenue - is that not possible?

2 · Reply

SnapCrackleStop Feb. 24 at 9:39 PM

$SCYX

0 · Reply

Market Cap	31.55M
Revenue (ttm)	3.75M
Net Income (ttm)	-21.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	0.73
Profit Margin	-567.73%
Debt to Equity Ratio	0.00

Volume	456,900
Avg Vol	446,236
Day's Range	N/A - N/A
Shares Out	41.97M
Stochastic %K	55%
Beta	1.33
Analysts	Strong Sell
Price Target	$3.67